D Aspartic Acid - NutraPedia
Back to Table of Contents
Research Overview
Across the studies reviewed here, D-aspartic acid (D-Asp) appears primarily in the context of “noncanonical neurotransmitters,” positioned alongside emerging signaling modalities (e.g., exosomes, steroids) rather than as a fully established transmitter class. The most studied area reflected here is its putative role in central nervous system signaling, especially in relation to excitatory neurotransmission frameworks that prominently feature glutamate and N-methyl-D-aspartate receptors (NMDARs). In parallel, several studies emphasize NMDAR-centered mechanisms in diverse neurological and systemic conditions—ischemia–reperfusion injury, hypoxic–ischemic encephalopathy, pain/central sensitization, Alzheimer’s disease, and hormone-related neuroprotection—providing a mechanistic landscape in which D-Asp is often discussed conceptually (as an NMDA-related amino acid signal) rather than as a clinically validated modulator.
The strongest support from these studies is therefore indirect: D-Asp is consistently treated as a plausible participant in excitatory signaling biology, within a broader body of evidence that NMDAR-mediated pathways are central to excitotoxicity, synaptic plasticity, neurodegeneration, and analgesia mechanisms. By contrast, the studies do not present direct interventional or clinical evidence demonstrating that manipulating D-Asp levels improves outcomes in these conditions. Instead, the most robust, clinically anchored evidence in the set pertains to NMDAR modulation more generally (e.g., memantine in Alzheimer’s disease; ketamine as an NMDAR antagonist with anesthetic/analgesic/antidepressant effects; therapeutic hypothermia in neonatal HIE affecting excitotoxic cascades), which supports the importance of the receptor system that D-Asp is hypothesized to influence.
Key gaps highlighted by this collection include the need for clearer causal and translational evidence specific to D-Asp: (i) mechanistic studies that quantify how endogenous D-Asp regulates NMDAR function in vivo across brain regions and developmental stages; (ii) disease-focused work that distinguishes D-Asp effects from broader glutamatergic signaling and from other modulators (e.g., steroids/IGF-1, Wnt pathway crosstalk); and (iii) human studies—biomarker, pharmacokinetic, and controlled interventional trials—testing whether D-Asp modulation meaningfully alters clinically relevant endpoints in conditions where NMDAR signaling is implicated (e.g., ischemic brain injury, chronic pain sensitization, neurodegeneration). Improved detection/measurement methods for D-Asp in biological matrices, and standardized approaches to manipulating its levels safely, would be enabling priorities for advancing from conceptual relevance to evidence-based therapeutic or diagnostic utility.
1. What conditions has D-Aspartic been studied for?
-
Neurological and neurodegenerative disorders (broad, non-specific): One abstract classifies D-aspartic acid as a “noncanonical neurotransmitter” and discusses that disturbances in neurotransmitter homeostasis are linked to many neurological and neurodegenerative disorders, but it does not name specific D-aspartate-targeted clinical indications or trials.
-
NMDA receptor–related excitotoxicity contexts (indirect relevance): Multiple studies discuss NMDA receptor involvement in conditions such as ischemia/hypoxia-related brain injury and Alzheimer’s disease, but these are largely about NMDA signaling generally (e.g., ketamine as an antagonist; memantine in AD; excitotoxicity in neonatal HIE), not about D-aspartate supplementation or D-aspartate as a treatment.
-
Diet/microbiome exposure (not a “condition”): D-Asp appears in studies about D-amino acids in fermented foods (black garlic) and D-amino acids produced by intestinal microbiota, indicating potential exposure routes rather than therapeutic study for a disease.
Bottom line: In the studies reviewed here, D-aspartic acid is mentioned mainly as a neurotransmitter-like molecule and as a D-amino acid present in foods/microbiota. The studies do not describe targeted clinical studies of D-aspartate as a treatment for a specific condition.
2. Does it work in treating those conditions? Summarize the evidence.
-
No direct efficacy evidence in these studies: None of the studies reviewed here report randomized trials, clinical outcomes, or even animal-model intervention results specifically testing D-aspartic acid administration for any condition.
-
Mechanistic plausibility is indirect and incomplete: Several studies emphasize the role of NMDA receptor signaling in excitotoxicity (e.g., hypoxic-ischemic encephalopathy mechanisms include “NMDA receptor hyperexcitability”) and in Alzheimer’s disease (memantine as an NMDA antagonist). Because D-aspartate is discussed as a neurotransmitter-like molecule, one could hypothesize it might interact with excitatory signaling, but the studies reviewed here do not test or confirm therapeutic benefit.
Conclusion: Based on these studies alone, there is insufficient evidence to claim D-aspartic acid “works” to treat any condition.
3. What health benefits does it have?
-
Potential role in neurotransmission/homeostasis (conceptual benefit): One abstract explicitly lists D-aspartic acid among “noncanonical neurotransmitters” and frames neurotransmitter modulation as a potential way to restore homeostasis in neurological conditions. This supports a theoretical role in brain signaling, but does not establish a supplement benefit.
-
Possible diet/microbiome-related exposure: D-aspartate is among multiple D-amino acids detected in black garlic (produced during fermentation) and among D-amino acids produced by intestinal microbiota. This suggests humans may be exposed to D-aspartate through diet and microbial metabolism, but the studies do not demonstrate a health outcome benefit from that exposure.
Important limitation: The studies reviewed here do not demonstrate concrete clinical benefits (e.g., improved cognition, mood, pain, stroke outcomes) attributable to D-aspartic acid itself.
4. Does it have any downsides or side effects?
-
No direct safety/side-effect data in these studies: None of the studies report adverse events, tolerability, dosing, or toxicity specifically for D-aspartic acid.
-
Potential theoretical concern—excitatory signaling: Several studies emphasize that excessive glutamatergic/NMDA activity is implicated in excitotoxic injury (e.g., neonatal hypoxic-ischemic encephalopathy includes “increased excitotoxicity” and “NMDA receptor hyperexcitability”). If D-aspartate participates in excitatory neurotransmission, a theoretical risk could be worsening excitotoxic pathways under certain conditions. However, the studies reviewed here do not establish that supplemental D-aspartate increases excitotoxicity in humans or animals.
Conclusion: From these studies, safety and side effects of D-aspartic acid supplementation cannot be determined; any discussion of harm is speculative without direct data.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
-
No pharmacogenomic evidence provided: None of the studies mention genetic variants (e.g., in NMDA receptor subunits, transporters, metabolic enzymes) that alter response to D-aspartic acid or change its risk/benefit profile.
Conclusion: Based on the studies reviewed here, there is no evidence to support D-aspartic acid being specifically beneficial or harmful for any known genetic variation.
D-Aspartic Acid in Neuroendocrine and Nervous Systems
D-Aspartic acid (D-Asp) is a naturally occurring amino acid with a pivotal role in the neuroendocrine and nervous systems of vertebrates and invertebrates. It is particularly concentrated during embryonic development in birds and early postnatal life in mammals, suggesting its importance in development. D-Asp acts as a neurotransmitter/neuromodulator, stimulates cAMP in neuronal cells, and is implicated in hormone synthesis and release, including testosterone and progesterone.
Interaction with NMDA Receptors
Both D-serine and D-Asp interact with NMDA receptors, with D-serine serving as a coagonist and D-Asp as an agonist. These interactions are relevant to neural diseases associated with NMDA receptor activity.
Presence in Mammals
D-Asp is found in significant levels in mammalian organs, particularly the central nervous system and endocrine glands. It displays a unique presence pattern, being abundant before birth and decreasing postnatally, potentially influencing hormone biosynthesis.
Role in Vertebrate Reproduction
Extensive research over two decades has linked D-Asp to various aspects of vertebrate reproduction, including hormone production and reproductive cell development. The amino acid may regulate reproductive cycles in wild animals and impact steroidogenesis and spermatogenesis in laboratory animals.
Effects on Testosterone Levels
Investigations into the effects of D-Asp on testosterone levels have yielded mixed results. Some animal studies indicate that D-Asp can increase testosterone, while human studies remain inconsistent. Further well-designed human clinical trials are necessary to clarify D-Asp's impact on testosterone concentrations.
Supplementation Studies in Resistance-Trained Men
Several studies have tested the effects of D-Asp supplementation on testosterone levels and training outcomes, with findings ranging from no change in testosterone or enhancement of training outcomes to a reduction in testosterone levels with higher D-Asp dosages.
Subacute Toxicity Study in Rats
Research on the subacute toxicity of D-Asp in rats has shown no evidence of toxicity when orally administered at tested doses. However, D-Asp did not increase its levels in the brain despite higher serum levels.
D-Asp as a Potential Neurotransmitter
Emerging evidence suggests that D-Asp may function as a classical neurotransmitter, stored in synaptic vesicles and elicits responses via ionotropic receptors, although D-Asp receptors remain to be fully characterized.
References:
- D-Aspartic acid: an endogenous amino acid with an important neuroendocrine role
- D-Amino acid metabolism in mammals: biosynthesis, degradation and analytical aspects of the metabolic study
- New Evidence on the Role of D-Aspartate Metabolism in Regulating Brain and Endocrine System Physiology: From Preclinical Observations to Clinical Applications
- D-Aspartic Acid in Vertebrate Reproduction: Animal Models and Experimental Designs‡
- The putative effects of D-Aspartic acid on blood testosterone levels: A systematic review
- The effects of d-aspartic acid supplementation in resistance-trained men over a three month training period: A randomised controlled trial
- D-aspartic acid supplementation combined with 28 days of heavy resistance training has no effect on body composition, muscle strength, and serum hormones associated with the hypothalamo-pituitary-gonadal axis in resistance-trained men
- Three and six grams supplementation of d-aspartic acid in resistance trained men
- Evaluation of D-amino acid levels in rat by gas chromatography-selected ion monitoring mass spectrometry: no evidence for subacute toxicity of orally fed D-proline and D-aspartic acid
- D-Aspartate acts as a signaling molecule in nervous and neuroendocrine systems
- Effects of pyridoxine on dreaming: a preliminary study
- A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study
-
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.
Meng Zhang, Qian Liu, Hui Meng, Hongxia Duan, Xin Liu, Jian Wu, Fei Gao, Shijun Wang, Rubin Tan, Jinxiang Yuan (2024) - Signal transduction and targeted therapy -
Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System.
Raluca Ioana Teleanu, Adelina-Gabriela Niculescu, Eugenia Roza, Oana Vladâcenco, Alexandru Mihai Grumezescu, Daniel Mihai Teleanu (2022) - International journal of molecular sciences -
Dual action of ketamine confines addiction liability.
Linda D Simmler, Yue Li, Lotfi C Hadjas, Agnès Hiver, Ruud van Zessen, Christian Lüscher (2022) - Nature -
Taurine and Astrocytes: A Homeostatic and Neuroprotective Relationship.
Sofía Ramírez-Guerrero, Santiago Guardo-Maya, Germán J Medina-Rincón, Eduardo E Orrego-González, Ricardo Cabezas-Pérez, Rodrigo E González-Reyes (2022) - Frontiers in molecular neuroscience -
Acupuncture-Analgesia-Mediated Alleviation of Central Sensitization.
Hsiang-Chun Lai, Yi-Wen Lin, Ching-Liang Hsieh (2019) - Evidence-based complementary and alternative medicine : eCAM -
Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target.
Nidhi Puranik, Minseok Song (2024) - Molecules (Basel, Switzerland) -
From Menopause to Neurodegeneration-Molecular Basis and Potential Therapy.
Yu-Jung Cheng, Chieh-Hsin Lin, Hsien-Yuan Lane (2021) - International journal of molecular sciences -
The diverse effects of ketamine, jack-of-all-trades: a narrative review.
Nicholas D Richards, Simon J Howell, Mark C Bellamy, James Beck (2025) - British journal of anaesthesia -
The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status.
John Sieh Dumbuya, Lu Chen, Jang-Yen Wu, Bin Wang (2021) - Journal of neuroinflammation -
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions.
Vern Lewis, Gareth Rurak, Natalina Salmaso, Argel Aguilar-Valles (2024) - Trends in neurosciences -
Determination of d- and l-Amino Acids in Garlic Foodstuffs by Liquid Chromatography-Tandem Mass Spectrometry.
Mayu Onozato, Haruna Nakanoue, Tatsuya Sakamoto, Maho Umino, Takeshi Fukushima (2023) - Molecules (Basel, Switzerland) -
Free D-amino acids produced by commensal bacteria in the colonic lumen.
Mitsuharu Matsumoto, Akihiro Kunisawa, Takanari Hattori, Shuichi Kawana, Yusuke Kitada, Hazuki Tamada, Shinichi Kawano, Yoshihiro Hayakawa, Junko Iida, Eiichiro Fukusaki (2018) - Scientific reports -
Salidroside derivative SHPL-49 attenuates glutamate excitotoxicity in acute ischemic stroke via promoting NR2A-CAMKⅡα-Akt /CREB pathway.
Dong Xie, Pei Zhang, Suxin You, Yue Shen, Wenwen Xu, Changsen Zhan, Jiange Zhang (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology -
AMPA receptors in Alzheimer disease: Pathological changes and potential therapeutic targets.
Luying Ning, Rongjing Shen, Bingqing Xie, Yong Jiang, Xiaoqi Geng, Wei Dong (2024) - Journal of neuropathology and experimental neurology -
Src-family protein tyrosine kinases: A promising target for treating chronic pain.
Meng-Meng Ge, Ya-Qun Zhou, Xue-Bi Tian, Anne Manyande, Yu-Ke Tian, Da-Wei Ye, Hui Yang (2020) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie -
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Fanshi Zhang, Mei Liu, Jinmei Tuo, Li Zhang, Jun Zhang, Changyin Yu, Zucai Xu (2023) - Frontiers in immunology -
Neurotoxicity of lead. Hypothetical molecular mechanisms of synaptic function disorders.
Irena Baranowska-Bosiacka, Izabela Gutowska, Marta Rybicka, Przemysław Nowacki, Dariusz Chlubek (2012) - Neurologia i neurochirurgia polska -
Glucose-6-phosphate dehydrogenase alleviates epileptic seizures by repressing reactive oxygen species production to promote signal transducer and activator of transcription 1-mediated N-methyl-d-aspartic acid receptors inhibition.
Liqin Hu, Yan Liu, Ziwei Yuan, Haokun Guo, Ran Duan, Pingyang Ke, Yuan Meng, Xin Tian, Fei Xiao (2024) - Redox biology -
Organotypic cultures as tools for optimizing central nervous system cell therapies.
Nicolas Daviaud, Elisa Garbayo, Paul C Schiller, Miguel Perez-Pinzon, Claudia N Montero-Menei (2013) - Experimental neurology -
In vitro effects of zinc, D-aspartic acid, and coenzyme-Q10 on sperm function.
Filippo Giacone, Rosita A Condorelli, Laura M Mongioì, Valentina Bullara, Sandro La Vignera, Aldo E Calogero (2017) - Endocrine
Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!
This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.
Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!